The Effect of Fluvastatin Treatment in Patients With Metabolic Syndrome

This study will evaluate the safety, efficacy and tolerability of fluvastatin extended release (80 mg once daily) in patients with metabolic...

Date First Received: April 21, 2008

Last Updated: April 22, 2008

Verified by: Novartis, April 2008

Clinical Trial Phase: Phase 4 | Start Date: September 2006

Overall Status: Completed

Estimated Enrollment: 878

Brief Summary

Official Title: “The Effect of Fluvastatin Treatment on the Lipid Profile in Patients With Metabolic Syndrome”

Condition Keyword(s):

Intervention(s):

This study will evaluate the safety, efficacy and tolerability of fluvastatin extended release (80 mg once daily) in patients with metabolic syndrome

Study Type: Interventional

Study Design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Study Primary Completion Date: October 2007

Intervention(s) in this Clinical Trial

  • Drug: fluvastatin
    • 80 mg once daily

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: 1

Outcome Measures for this Clinical Trial

Primary Measures

  • Change from baseline in total cholesterol levels at 6 weeks
    • Time Frame: 6 weeks
      Safety Issue?: No

Secondary Measures

  • Adverse Events
    • Time Frame: 6 weeks
      Safety Issue?: Yes

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Male or female patients > 20 years of age
  • Patients meeting at least three criteria for metabolic syndrome
  • Triglycerides levels < 400 mg/dl and LDL cholesterol levels between 100 mg/dl and 190 mg/dl
  • Written consent for participating in the study
  • Patients who are able to communicate and able to follow all the requirements

Exclusion Criteria:

  • Patients with severe renal disease or renal dysfunction
  • Patients with chronic liver disease or liver function impairment
  • Patients with inflammatory muscle dysfunction or findings of muscle problems
  • Patients with severe cardiac failure
  • Patients with findings of any cardiovascular event within the last 6 months Other protocol-defined inclusion/exclusion criteria may apply

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 20 Years

Maximum Age for this Clinical Trial: 90 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: Novartis

Additional Information

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00664742

Study ID Number: CXUO320BTR03

ClinicalTrials.gov Identifier: NCT00664742

Health Authority: Turkey: Ministry of Health

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.